Here is a January 2026 comprehensive review of commonly used and esoteric hemostasis disorder biomarkers in downloadable format: Reardon B, Pasalic L, Favaloro EJ. Biomarkers of coagulation disorders—where to from here? Biomolecules 2026: 16, 235. https://doi.org/10.3390/biom16020235.
Abstract
Disorders of thrombosis and bleeding contribute to a significant morbidity and mortality burden worldwide. Correctly identifying contributing factors towards either thrombosis or bleeding carries implications for diagnosis, prognosis, and management. Although there are established and commonly used biomarkers for both circumstances, the complexity of hemostasis contributes to the wide variability in assay methodology and information provided by each individual assay. There are several emerging biomarkers of thrombosis and hemostasis, which require further evaluation of their roles in diagnosis and management in specific patient populations. This narrative review summarizes established, emerging, and exploratory biomarkers of both thrombosis and bleeding disorders, outlining their bio-logical roles, diagnostic utility, and limitations, with a particular focus on clinical relevance, assay methodology and future directions.
No comments here.